Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understandi...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
KeAi Communications Co., Ltd.
2019
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c65a4a41082d4663a0cc81b8d4f5703e |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types. By introducing the anti-tumor behaviors and the potential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms. Keywords: THZ1, Cyclin-dependent kinase 7, Cancer therapy, Transcription, Super-enhancer |
|---|